Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018



Rating:

Share or cite this content

Citations should be made in the following way:
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux. The potential impact of azithromycin in idiopathic pulmonary fibrosis. Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 The changing treatment landscape in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 65-68 Year: 2015 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1434-1445 Year: 2015 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006